Latest News for: s1p

Edit

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P ...

The Eagle-Tribune 21 Dec 2023
(NYSE.BHC)(TSX.BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis (UC).
Edit

Bausch Health Announces Positive Topline Results From Global Phase 2 Study Evaluating Amiselimod (an S1P antagonist) to Treat Ulcerative Colitis

Pharmiweb 21 Dec 2023
(NYSE.BHC)(TSX.BHC) ("Bausch Health" or the "Company") today announced positive topline results from the Company's Phase 2 study evaluating Amiselimod, an investigative S1P antagonist, for the treatment of ulcerative colitis (UC).
Edit

Can BMS' Zeposia Cement a Defensible Market Position in Ulcerative Colitis Ahead of Pfizer's Potential Rival S1P treatment, etrasimod? According to Spherix Global Insights

PR Newswire 09 Feb 2023
EXTON, Pa., Feb ... Expectations for the S1P class were also considered in the analysis ... Both findings suggest a majority of physicians have a favorable opinion of the S1P mechanism ... One-third of physicians reported being highly likely or likely to do so ... .
Edit

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

Nasdaq Globe Newswire 09 Nov 2022
TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia ... .
  • 1

Most Viewed

×